Cardiovascular magnetic resonance of left ventricular pseudoaneurysm
暂无分享,去创建一个
D. Pennell | J. Peters | P. McEwan | C. Currie | C. Morgan | J. Goodfellow | M Jones | P McEwan | C Ll Morgan | J R Peters | J Goodfellow | C J Currie | A. Varghese | M. Jones | John Pepper
[1] G. Lip,et al. Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.
[2] D. Fitzmaurice,et al. Recommendations for patients undertaking self management of oral anticoagulation , 2001, BMJ : British Medical Journal.
[3] H. Mcelroy,et al. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment , 1998, BMJ.
[4] Heather L. Heiman,et al. Contributions Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation , 2001 .
[5] J. Peters,et al. Patterns and costs of hospital care for coronary heart disease related and not related to diabetes , 1997, Heart.
[6] F R Rosendaal,et al. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.
[7] Carl van Walraven,et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. , 2002, JAMA.
[8] D. Fitzmaurice,et al. Does the Birmingham model of oral anticoagulation management in primary care work outside trial conditions? , 2001, The British journal of general practice : the journal of the Royal College of General Practitioners.
[9] Leandro Provinciali,et al. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .
[10] M. Šabovič,et al. Intensity of Long-Term Treatment with Warfarin Is Influenced by Seasonal Variations , 2002, Pathophysiology of Haemostasis and Thrombosis.
[11] D. Anderson,et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[12] Valentin Fuster,et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. , 2003, Circulation.
[13] J. McMurray,et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK , 2004, Heart.
[14] M. Prins,et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison , 2000, The Lancet.
[15] L. Kalra,et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness , 2000, BMJ : British Medical Journal.
[16] R. Hatala,et al. Anticoagulants for atrial fibrillation: Why is the treatment rate so low? , 2002, Clinical cardiology.
[17] M. Goldacre,et al. Computerised linking of medical records: methodological guidelines. , 1993, Journal of epidemiology and community health.
[18] L. Gill,et al. Epidemiology and costs of acute hospital care for cerebrovascular disease in diabetic and nondiabetic populations. , 1997, Stroke.
[19] Ralph B D'Agostino,et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. , 2003, JAMA.
[20] M. Prins,et al. Comparison of Three Methods to Assess Therapeutic Quality Control of Treatment with Vitamin K Antagonists , 1999, Thrombosis and Haemostasis.
[21] G. Lip,et al. Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.